Clinical Medicine III. Posters
Dr. Dániel, Seidl
MTA-SE Lendület Nephrogenetic Laboratory, Hungarian Academy of Sciences; First Department of Pediatrics, Semmelweis University
+36207700805
seidl.daniel@med.semmelweis-univ.hu
Penetrance of the CFTR 5T Allele in Congenital Bilateral Absence of the Vas Deferens
Dániel Seidl1,2, Ágnes Mikó1,2, Ambrus Kaposi1, Kálmán Tory1,2
1MTA-SE Lendület Nephrogenetic Laboratory, Hungarian Academy of Sciences
2First Department of Pediatrics, Semmelweis University, 1083, Budapest, Hungary
Clinical Medicine III. Posters
Hungarian
Clinical Medicine
Theoretical and Translational Medicine
Introduction: Congenital bilateral absence of the vas deferens (CBAVD) is responsible for 2% of male infertility. One third (25-40%) of patients with CBAVD are compound heterozygous for the CFTR 5T (c.1210-7_1210-6delTT) variant and another variant in trans. The 5T allele, with a MAF of 3% in the general European population, causes the loss of exon 10 in 95% of mRNA.
Aims: Using a formerly developed population-genetic algorithm we aimed to assign the penetrance of the 5T variant.
Method: We collected phenotype and genotype data from 3279 patients with biallelic CFTR mutations from PubMed. The penetrance (P) of the 5T variant was calculated by comparing its allele count (AC) to the AC of the loss-of-function (LOF) variants in the European non-Finnish patient population and in the gnomAD as P=(AC5T/ACLOF)patient/(AC5T/ACLOF)gnomAD, tested by Fisher’s exact test.
Results: We found the 5T allele in 339/3279 (10.34%) patients, trans-associated to LOF mutations in 187/635 (29.3%) of the patients with CBAVD. None of the compound heterozygous patients with the 5T allele (without other variant in cis) developed CF. We found the penetrance of the 5T variant to be 4.3% (p=5x10-389).
Conclusions: According to our penetrance estimation, for a couple with heterozygous CFTR 5T allele in one parent and a LOF variant in another, the risk of a son being affected by CBAVD is 1% (25% x 4.3%).
Supported by the ÚNKP-19-3-II New National Excellence Program of the Ministry for Innovation and Technology.
Supervisor: Kálmán Tory
E-mail address: tory.kalman@med.semmelweis-univ.hu
Poszter
Szabad
elfogadva
poszter
nem rendelkezett róla
4771
12:28
12:31
Dániel Seidl1,2, Ágnes Mikó1,2, Ambrus Kaposi1, Kálmán Tory1,2
1MTA-SE Lendület Nephrogenetic Laboratory, Hungarian Academy of Sciences
2First Department of Pediatrics, Semmelweis University, 1083, Budapest, Hungary